This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pacira Pharmaceuticals Inc (PCRX)

NASDAQ: Health Care

Company Cash Flow
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Cash Flow From Operating Activities
Net Income (Loss) -13.72M -63.91M -52.28M -43.33M
Operating Gains/Losses 158.00K 3.43M 1.06M 273.00K
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables -7.78M -10.24M -2.24M -922.00K
(Increase) Decrease in Inventories -13.71M -3.48M -10.83M 360.00K
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 14.00K
(Decrease) Increase In Payables 14.25M 10.24M 1.39M 2.55M
(Decrease) Increase In Other Current Liabilities 0.00 0.00 0.00 0.00
(Increase) Decrease In Other Working Capital 8.22M 31.00K -18.18M 1.09M
Other Non-Cash Items 24.82M 11.51M 4.78M 3.70M
Net Cash From Continuing Operations 25.47M -43.22M -70.13M -31.00M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 25.47M -43.22M -70.13M -31.00M
Sale of Property, Plant & Equipment 0.00 0.00 1.00K 14.00K
Cash Used for Investing Activities
Sale of Short-Term Investments 80.29M 85.56M 53.12M 0.00
Purchases of Property, Plant & Equipment -21.89M -12.79M -18.26M -6.17M
Acquisitions 0.00 0.00 0.00 0.00
Purchases of Short-Term Investments -139.84M -114.30M -54.05M -29.97M
Other Cash from Investing Activities -13.43M -2.03M -10.34M 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities -119.34M -43.56M -29.52M -36.12M
Issuance of Debt 0.00 120.00M 27.50M 0.00
Cash Used for Financing Activities
Issuance of Capital Stock 118.88M 3.86M 63.72M 87.16M
Repayment of Long-Term Debt 0.00 -27.50M -26.25M 0.00
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net 0.00 -7.19M -1.36M 0.00
Net Cash From Financing Activities 118.88M 89.16M 63.61M 87.16M
Effect of Exchange Rate Changes 0.00 0.00 0.00 0.00
Net Change in Cash & Cash Equivalents 25.00M 2.39M -36.04M 20.04M
PCRX News

PCRX Pacira Pharmaceuticals Inc

Analysts Ratings for PCRX

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 6 6 6 5
Moderate Buy 0 0 0 0
Hold 0 0 0 1
Moderate Sell 1 1 1 0
Strong Sell 0 0 0 0
GET PCRX ANALYST REPORT

Brokerage Partners

PCRX Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs